Drugmaker Pfizer, New York, and device firm Gyrus Group, of London, announced separate deals to expand their product lines. Pfizer said it would buy Vicuron Pharmaceuticals, King of Prussia, Pa., which makes anti-infection drugs, for $1.9 billion. Gyrus announced plans to acquire ACMI Corp., Southborough, Mass., a urology and gynecology endoscopy company, for approximately $500 million -- 88% in cash and 12% in Gyrus stock, representing 9% of the company. Pfizer said it expects to complete its purchase of Vicuron in the third quarter, pending approval by regulators and Vicuron shareholders. Gyrus' acquisition of ACMI is expected to close in July, subject to regulatory approval. Private equity firm Fox Paine and Co., San Francisco, which controls ACMI, will receive the right to appoint one member of the Gyrus board. Officials said the deal would let ACMI expand beyond the urology and gynecology practice areas. -- by Cinda Becker
Acquisitions announced in drug, device industries
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.